Related by context. All words. (Click for frequent words.) 72 Intervention Effectiveness 68 evaluating Actimmune 68 ExTRACT TIMI 68 BRIM2 68 ACTIVE W 68 Clinical Antipsychotic Trials 68 CARE HF 68 blinded randomized placebo controlled 67 relapsed MM 67 placebo controlled clinical 67 randomized controlled multicenter 67 CLARITY TIMI 67 EURIDIS 66 BRIM3 66 Intervention Effectiveness CATIE 66 Phase Ib IIa 65 CAMMS# 65 dose escalation clinical 65 multicenter randomized controlled 65 NSABP B 65 relapsing remitting MS RRMS 65 designated HVTN 65 double blinded randomized 65 Randomized Phase II 65 Edge STudy 65 placebo controlled Phase 65 multicentre prospective 65 Randomized Phase 65 alvespimycin 65 phase IIa clinical 64 multicentre randomized 64 Phase 1a clinical 64 placebo controlled Phase III 64 landmark ATHENA 64 Phase III placebo controlled 64 Phase III multicenter 64 MADIT II 64 Multiple Ascending Dose 64 Sprycel dasatinib 64 SPIRIT FIRST 64 dose escalation phase 64 TMC# C# 64 Phase IIIb clinical 64 blinded placebo controlled 64 number NCT# ClinicalTrials.gov 64 CHAMPION PCI 64 phase IIIb 64 ONTARGET 64 HCV SPRINT 64 Carotid Revascularization Endarterectomy vs. 64 multicentre randomized controlled 64 Bayer HealthCare Onyx Pharmaceuticals 64 Truvada tablets 64 treatment naive genotype 64 interferon gamma 1b 63 ADVANCE PD 63 multicenter Phase II 63 PD LID 63 AIM HIGH 63 registrational Phase 63 phase IIa 63 evaluating mipomersen 63 recurrent glioblastoma multiforme 63 RE LY ® 63 multicenter placebo controlled 63 CALGB 63 Phase Ib clinical 63 Phase III ThermoDox 63 MERLIN TIMI 63 BCIRG 63 phase Ib 63 STRIDE PD 63 Phase Ib II 63 XL# SAR# 63 Multicenter Automatic Defibrillator Implantation 63 multicenter multinational 63 Randomized controlled 63 Initiated Phase 63 Phase #b/#a clinical 63 prospective multicenter randomized 63 RECORD1 63 phase IIb clinical 63 ORAL Sync 63 EDEMA3 63 placebo controlled multicenter 63 confirmatory clinical 62 PreCISe 62 APEX PD 62 REMINYL ® 62 Phase IIb III 62 ENESTnd 62 ABSORB clinical 62 multicenter randomized placebo controlled 62 oral rivaroxaban 62 Phase III AFFIRM 62 ECASS 62 GOUT 62 HYVET 62 Prednisone Against Refractory 62 prospective multicentre 62 ongoing Phase 1b 62 VICTOR E1 62 PSMA ADC 62 AIR CF2 62 retinal vein occlusion induced 62 GAMMAGARD 62 tramiprosate Alzhemed TM 62 placebo controlled randomized 62 HF ACTION 62 Phase IIIb 62 MGd 62 brivaracetam 62 CURRENT OASIS 7 62 PLX STROKE targeting 62 Zemplar Capsules 62 randomized multicentre 62 dimebon latrepirdine 62 galiximab 62 tarenflurbil 62 multicenter prospective 62 Prostate AdenoCarcinoma Treatment 62 Val HeFT 62 azilsartan medoxomil 62 PFO migraine 62 multicenter Phase III 62 EVEREST II 62 Rilonacept 62 oral FTY# 62 prospective nonrandomized 62 EXPLORE Xa 62 AVOREN 62 ORACLE MS 62 MEND CABG 61 + Perifosine Evaluation 61 randomized multicenter 61 ENDEAVOR IV 61 Alzheimer Disease Cooperative 61 multicenter Phase 61 refractory chronic lymphocytic 61 acute mania 61 EchoCRT 61 Phase III VISTA 61 forodesine 61 PRECiSE 61 IMPACT DCM 61 evaluating Vectibix 61 AVADO 61 subcutaneous PRO 61 riociguat 61 R roscovitine 61 Randomized Evaluation 61 novel VDA molecule 61 trial evaluating PRX# 61 Aggressive Reduction 61 CIMZIA TM certolizumab pegol 61 mITT population 61 TG MV 61 Folfox 61 multicenter randomized clinical 61 CONQUER OB 61 SUTENT ® 61 ONTARGET R 61 Randomized Double Blind 61 evaluating tivozanib 61 Heterozygous Familial Hypercholesterolemia 61 Aplidin R 61 PERSEUS clinical program 61 Xelox 61 ALN VSP Phase 61 Pivotal Phase III 61 Celecoxib APC trial 61 Initiate Phase 61 recurrent malignant glioma 61 acyclovir Lauriad R 61 Prostate Lung Colorectal 61 PHX# 61 multicentre randomized double 61 ADMIRE HF 61 prospectively stratified 61 PEG SN# 61 Multicenter Phase 61 SPIRIT IV 61 MAGE A3 ASCI 61 RLAI 61 comparing XIENCE V 61 Phase 2b kidney transplant 61 INSPIRE Trial Phase III 61 REVIVE Diabetes 61 prospective randomized multicenter 61 Combination REOLYSIN R 61 controlled multicenter 61 LUX Lung 61 Acute Decompensated Heart Failure 61 active comparator 61 virus HCV protease inhibitor 61 randomized Phase IIb 61 mg administered orally 61 CYT# potent vascular disrupting 61 MIST II 61 CALGB # [002] 61 SPRYCEL ® 61 Wisconsin Sleep Cohort 61 Cholesterol Levels SPARCL 60 tanespimycin 60 Severe Sepsis 60 REVIVE TA 60 evaluating satraplatin 60 midstage clinical 60 tenofovir emtricitabine 60 ZYBRESTAT fosbretabulin 60 desvenlafaxine succinate 60 Raloxifene Evaluation MORE 60 NO# [002] 60 RE LY 60 BR.# 60 opioid naive 60 Alpha Tocopherol Beta Carotene 60 recurrent metastatic ovarian cancer 60 candesartan cilexetil 60 ThermoDox ® clinical 60 Sapacitabine 60 blinded randomized 60 Oral Fingolimod 60 HORIZONS AMI 60 Phase III randomized 60 ASTEROID 60 Pivotal Phase 60 ROCKET AF 60 retrospective observational 60 COR Diabetes 60 multicenter randomized double 60 Phase IIA 60 pivotal bioequivalence 60 Controlled Trial 60 AIR2 Trial 60 TAXUS VI 60 Tramiprosate ALZHEMED TM 60 AIR CF1 60 LUMINATE 60 Quinamed 60 weekly subcutaneous injections 60 daily Infergen 60 Decompensated Heart Failure 60 dirucotide MBP# 60 lorcaserin Phase 60 double blinded placebo 60 Randomized Double blind 60 prospective randomized placebo 60 Sipuleucel T 60 CAPRIE 60 MADIT 60 DASISION 60 Glucosamine Chondroitin Arthritis 60 NCCTG N# 60 Testosterone MDTS ® 60 ENDEAVOR III 60 metastatic colorectal carcinoma 60 DEB# 60 VADT 60 Phase III ADT 60 SYMMETRY trial 60 Refractory Angina 60 ACTEMRA TM 60 NEVO RES 60 bepotastine besilate nasal spray 60 lenalidomide Revlimid R 60 Meets Primary Endpoint 60 metastatic hormone refractory 60 Myocardial Infarction Study 60 blinded randomized controlled 60 randomized controlled Phase 60 PF # [002] 60 AVERROES 60 recombinant PSMA vaccine 60 Recurrent Glioblastoma 60 HCV RESPOND 2 60 CIMZIA ™ 60 Phase III randomized controlled 60 Pegylated Liposomal Doxorubicin 60 Randomized Phase III 60 naïve HCV 60 PLCO 60 -#.# log# copies mL 60 evaluating satraplatin plus 60 TAXUS IV 59 TELINTRA R 59 APPRAISE 59 CALERIE 59 TRA 2P 59 Phase #/#a 59 UKPDS 59 Trandolapril 59 Safinamide 59 BARI 2D 59 Clinicaltrials.gov 59 induced macular edema 59 Completes Patient Enrollment 59 somatostatin analog 59 MEND CABG II 59 phase IIb 59 Phase lll 59 modified REGENESIS Phase IIb 59 randomized Phase III 59 relapsed refractory multiple myeloma 59 Hepatotoxicity 59 Acute Ischemic Stroke 59 BOLDER II 59 TDF FTC 59 avosentan 59 By JENNIFER LEARN 59 Aflibercept 59 systemic anaplastic large 59 SPARCL 59 Degarelix 59 multicenter phase 59 antiretroviral naive 59 generalized anxiety disorder GAD 59 BENICAR HCT 59 Randomised 59 Oral NKTR 59 insulin detemir 59 Phase 2a Trial 59 antidepressants fluoxetine 59 COU AA 59 Prospective Randomized 59 Teriflunomide 59 Diabetic Macular Edema 59 Hormone Refractory Prostate Cancer 59 Dialysis Outcomes 59 atazanavir ritonavir 59 substudy 59 ATACAND 59 PREZISTA r 59 subanalysis 59 Androxal TM 59 Acute Myocardial Infarction 59 NCT# ClinicalTrials.gov 59 Relapsing Multiple Sclerosis 59 Initiates Phase II 59 XIENCE V Stent System 59 Vitaxin 59 controlled dose escalation 59 Tanespimycin 59 Trofex 59 ACCOMPLISH 59 EmbraceAC 59 VELCADE melphalan 59 cisplatin gemcitabine 59 irbesartan 59 Phase IIb clinical 59 randomized multicenter trial 59 ADVANCE ILLUMINATE 59 PERSEUS 59 canakinumab 59 olanzapine LAI 59 Perifosine KRX 59 ARIXTRA R 59 IIb clinical trial 59 Primary endpoints 59 OPT CHF 59 Phase III Pivotal 59 thorough QT 59 Phase 1b clinical 59 masked placebo controlled 59 deCODE AF TM 59 E1 INT TM 59 MIVI III 59 multicenter randomized 59 CIMZIA TM 59 Phase 1b clinical trials 59 Pooled Analysis 59 CAPACITY trials 59 insulin glulisine 59 prospective observational studies 59 Randomized Controlled 59 multicenter clinical 59 primary hypercholesterolemia 59 Cimzia ® certolizumab pegol 59 RhuDex 59 Spine Patient Outcomes 59 Active Ulcerative Colitis 59 ID NCT# 59 Digital Mammographic Imaging 59 ABCSG 59 YONDELIS 59 myocardial infarction ventricular fibrillation 59 Motesanib 59 catheter occlusion 59 Sibutramine Cardiovascular Outcomes 59 ASCEND HF 59 Mg Usa 59 PROSTVAC TM 59 MIRAPEX 59 epoetin alpha 59 COPERNICUS 59 Unstable Angina 59 compound INCB# 59 icatibant 59 Empatic ™ 59 fosbretabulin 59 DIRECT Trial 59 evaluating REVLIMID 59 ACUITY trial 59 ascending dose 59 CUSTOM II 59 RIO Lipids 59 placebo PBO 58 metastatic GIST 58 HPTN 58 First Patient Enrolled 58 treatment naïve genotype 58 AVN# Phase 58 WHIMS 58 R#/MEM 58 eszopiclone 58 label multicenter randomized 58 NATRECOR ® 58 glulisine 58 intensive lipid lowering 58 morphometric vertebral fractures 58 Naive Patients 58 HORIZONS AMI trial 58 ORENCIA ® 58 R#/MEM # 58 venlafaxine XR 58 divalproex sodium 58 FOLOTYN ® 58 National Emphysema Treatment 58 Capesaris 58 Second Pivotal Phase 58 randomized blinded 58 demonstrated antitumor activity 58 Cloretazine 58 colesevelam HCl 58 plus COPEGUS 58 randomized discontinuation 58 Arch Neurol 58 Prostate Cancer Prevention 58 R# #mg BID 58 PRE SURGE 58 Phase 2a clinical 58 elotuzumab 58 Phase IIB 58 reduce serum phosphate 58 Kahalalide F 58 Placebo controlled 58 Proellex TM 58 Clinical Outcomes Utilizing Revascularization 58 Phase IIa clinical 58 recurrent metastatic 58 CEQ# 58 Novel Oral 58 stage IIIb IV 58 nonrandomized 58 worsening thrombocytopenia 58 Chronic Heart Failure 58 EDEMA4 58 INCB# [001] 58 OncoVex 58 dependent kinase inhibitor 58 SORT OUT III 58 initiated Phase Ib 58 phase IIb trial 58 eosinophilic asthma 58 mertansine 58 FOLFOX6 chemotherapy regimen 58 FDA defined valvulopathy 58 kidney urologic 58 MIRAPEX ER 58 dosing cohorts 58 Urocortin 2 58 budesonide MMX Phase III 58 CLARITY study 58 clevidipine 58 Mg Uk 58 Temsirolimus 58 Antihypertensive 58 Phase 2b clinical 58 GATTEX ® 58 Pimavanserin 58 PROTECT AF 58 GENASIS clinical 58 placebo controlled dose escalation 58 ACCORD Eye 58 trastuzumab emtansine T DM1 58 phase Ib clinical 58 orally inhaled migraine 58 rALLy clinical trial 58 TMC# [002] 58 prospective observational cohort 58 EQUIP OB 58 everolimus eluting stents 58 WHEL 58 PROactive study 58 Pre RELAX AHF 58 PDE# inhibitors 58 RhuDex ® 58 Lu AA# 58 Subgroup analysis 58 IMPACT IMmunotherapy 58 Initiates Phase III 58 PRIMO CABG 58 prelicensure 58 complement inhibitor eculizumab 58 NATRECOR R 58 VIVITROL ® 58 LAB CGRP 58 levodopa induced dyskinesia 58 novel orally inhaled 58 hyperphenylalaninemia HPA due 58 8mg/kg 58 ALISTA TM 58 Tumor Response 58 STEP BD 58 RRMS patients 58 HDL Selective Delipidation 58 pharmacogenomic translational research 58 paricalcitol 58 de novo kidney transplant 58 sitaxsentan 58 ASSERT 58 GATTEX ™ 58 Sequenced Treatment Alternatives 58 irinotecan cisplatin 58 viral kinetics 58 paclitaxel poliglumex 58 assessing T DM1 58 evaluating carfilzomib 58 pegylated liposomal doxorubicin 58 reslizumab 58 PARTNER Trial 58 INTEGRILIN R 58 heFH 58 sorafenib tablets 58 Left Ventricular Dysfunction 58 Phase #b/#a 58 Hepatocellular Carcinoma HCC 58 HBeAg negative 58 Multicenter Randomized 58 NCCTG 58 ULORIC 58 gastrin analogue TT 58 Ischemic 58 alfa 2a 58 AE# vaccine 58 DAPT 58 RELOVAIR ™ 58 REALITY Trial 58 MVA MUC1 IL2 58 NuroPro PD 58 biliary tract cancer 58 CCX# B 58 lumiliximab 58 XIENCE V demonstrated 58 mg BID dose 58 Placebo Controlled 58 Patients Treated With 58 BEZ# 58 confirmatory Phase III 58 LymphoStat B belimumab 58 Phase 2a trial 58 ANCHOR trial 58 OvaRex ® MAb 58 Phase III HEAT 58 Prospective Multicenter 58 CML CP 57 Demonstrates Sustained 57 Cutaneous T 57 dyskinesia PD LID 57 evaluating T DM1 57 label multicenter Phase 57 ARCOXIA 57 trials RCTs 57 TBC# 57 refractory acute myeloid 57 PEGINTRON TM 57 dose dose escalation 57 oral sapacitabine 57 Medullary Thyroid Cancer 57 Polyp Prevention Trial 57 Intervention Trial GAIT 57 5 fluorouracil leucovorin 57 metaglidasen 57 TLK# 57 NOXAFIL Oral Suspension 57 teriflunomide 57 antiretroviral naïve 57 dosing cohort 57 CCR5 mAb 57 PANVAC VF 57 Aggressive Drug Evaluation 57 toenail onychomycosis 57 experimental allergic encephalomyelitis 57 prospective multicenter 57 CHARM Added 57 Plicera 57 Screening Trial DMIST 57 paclitaxel eluting stents 57 randomized Phase 2b 57 aplindore 57 Intravenous CP 57 oral picoplatin 57 lintuzumab SGN 57 Investigational Treatment 57 ToGA 57 Azacitidine 57 Dose Escalation 57 Lipid Lowering Treatment 57 sunitinib malate 57 NSABP C 57 Testosterone MDTS R 57 phase IIb study 57 gemcitabine Gemzar ® 57 Hepsera adefovir dipivoxil 57 Zenvia Phase III 57 Stop Hypertension DASH 57 ADAGIO study 57 Prodarsan R 57 Phase IIb Trial 57 Confirmatory Phase 57 KRN# 57 huC# DM4 57 vaso occlusive crisis 57 CTAP# Capsules 57 Asthma Intervention 57 LibiGel Phase III 57 volociximab 57 telaprevir dosing 57 null responder HCV 57 GISSI HF 57 Randomized Clinical Trial 57 EINSTEIN DVT 57 Tipranavir 57 RCW breast cancer 57 II Clinical Trial 57 AZOR 57 recurrent glioma 57 telaprevir dosed 57 Raptiva r 57 Advanced Melanoma 57 ® pioglitazone HCl 57 orally administered inhibitor 57 Hsp# Inhibitor 57 Pivotal Trial 57 Major Depressive Disorder 57 overt nephropathy 57 Diamyd r 57 Oral Calcitonin 57 Secondary efficacy endpoints 57 randomized controlled clinical 57 Dose escalation 57 Phase IIIb study 57 ThermoDox R 57 Cetrorelix 57 NLX P# 57 Xcellerated T Cells 57 anagrelide 57 unstable angina UA 57 genotypic resistance 57 evaluating tesamorelin 57 #rd Annual CTRC 57 ICON7 57 STRATEGY FOR AN OPEN 57 MMX mesalamine 57 recombinant tissue plasminogen 57 randomized multicenter Phase III 57 AML MDS 57 Tolvaptan 57 mGluR5 NAM 57 AAG geldanamycin analog 57 Tasigna prolongs 57 PIX# [002] 57 interferon beta 1b 57 vidofludimus 57 Alzhemed TM 57 clinical pharmacology studies 57 certolizumab 57 CG# oncolytic virus 57 TASKi3 57 ORAL Solo 57 Arch Intern Med 57 visilizumab 57 Thiarabine 57 #mg/day [001] 57 MYTHOS trial 57 recurrent NSCLC 57 Aeolus Pharmaceuticals Announces 57 doxorubicin cyclophosphamide 57 randomized discontinuation trial 57 meta regression 57 receptor tyrosine kinase inhibitor 57 Phase Ib Clinical Trial 57 LHON 57 Phase 2a clinical trials 57 HCD# [002] 57 ACRIN 57 Ziprasidone 57 ACCORD Lipid 57 HOPE TOO 57 mGluR2 NAM 57 Hodgkin lymphoma HL 57 AA Amyloidosis 57 Adjuvant Treatment 57 MOTIVATE 57 nitric oxide donating prostaglandin 57 Phase 2b Study 57 EMPHASIS HF 57 dapagliflozin plus 57 rufinamide 57 AKT inhibitor 57 prospective randomized controlled 57 Cerebril TM 57 RAPTIVA 57 CLL8 57 next generation URAT1 57 DAPT Study 57 TRITON TIMI 57 p# biomarker 57 ELACYT 57 Dextofisopam Phase 2b 57 CYP#A# CYP#D# 57 MADIT CRT 57 APTIVUS 57 Phase IIa trial 57 observational cohort 57 unfractionated heparin UFH 57 aripiprazole Abilify 57 PNP inhibitor 57 YOUR LOCAL ANIMAL SHELTER 57 oral ridaforolimus 57 chromium supplementation 57 TAXUS ATLAS 57 ELND# 57 DCCR 57 Curaxin CBLC# 57 EOquin TM 57 Brentuximab Vedotin SGN 57 Services #:#-#,# Abstract 57 prospectively defined 57 GVAX ® 57 Phase Ib study 57 keloid scarring 57 C1 INH deficiency 57 DSMB recommended 57 symptomatic BPH 57 Phase Ia 57 multicenter randomized Phase 57 postmenopausal osteoporotic women 57 IMPACT DCM clinical 57 via intradermal injections 57 Phase 2b monotherapy 57 ACCEDE 57 LT NS# 57 DermaVir Patch 57 neovascular form 57 Thorough QT 57 Trastuzumab DM1 57 zoledronic acid Reclast 57 Rigel R# 57 PET FROM 57 Phase IIa trials 57 SCIg 57 adult chronic ITP 57 Temodar ® 57 UVIDEM 57 Syncria albiglutide 57 SPIRIT III 57 PrevOnco 57 Ophena TM 57 ug dose 57 randomized crossover 57 PROSTVAC VF 57 REG2 57 CIMZIA R 57 NuroPro R 57 IIa trial 57 Vicriviroc 57 oral Janus kinase 57 pharmacokinetic PK study 57 SIMCOR 57 Genasense oblimersen sodium Injection 57 TORISEL TM 57 brivanib 57 selective modulator 57 PRESEPT 57 QLT# 57 APEX AMI 57 JAK2 Inhibitor 57 ELOXATIN 57 Angiox ® 57 Percutaneous Tibial Nerve Stimulation 57 AVONEX ® 57 PEGINTRON REBETOL combination 57 Phase III confirmatory 57 pharmacokinetic pharmacodynamic 57 Arch Surg 57 prospective observational 57 Renal Cell Carcinoma RCC 57 Subgroup Analysis 57 Systemic Sclerosis 57 Fibrillex TM 57 ZD# [001] 57 Anturol TM 57 PRECISE Trial 57 sargramostim 57 hoFH 57 non valvular atrial 56 atherothrombotic disease 56 Ovarian PLCO Cancer 56 blind multicenter 56 Cardiotoxicity 56 samalizumab 56 Diabetic Foot Ulcer 56 hypercholesterolemic patients 56 observational cohort study 56 Cimzia TM 56 Multicenter 56 Onrigin TM 56 sunitinib Sutent 56 VITAL Trial 56 psoriatic arthritis PsA 56 florbetaben 56 Group RTOG 56 ZOLINZA 56 metastatic castration resistant 56 noninvasive outpatient 56 visit http:/www.clinicaltrials.gov/ 56 PREVENT IV 56 RSD# oral 56 pegylated interferon alfa 2b 56 papillary renal cell carcinoma 56 Dacogen injection 56 AFREZZA TM 56 HuMax EGFr 56 MERIT ES 56 OMP #R# 56 multinational multicenter randomized 56 Stent Thrombosis 56 J Clin Endocrinol Metab 56 RhuDex TM 56 Certolizumab pegol 56 #:#-# [029] 56 AGILECT R 56 Phase III Trial 56 mcg linaclotide 56 GetGoal Phase III 56 Omacetaxine 56 #mg BID [001] 56 Bucindolol 56 Pirfenidone 56 Kinesin Spindle Protein KSP 56 Telik Announces 56 MKC# 56 β blockers 56 miconazole Lauriad ® 56 pravastatin Pravachol 56 including eniluracil ADH 56 dacetuzumab 56 GSK# [001] 56 ascending dose study 56 Diamyd Medical Diamyd 56 randomized #:#:# 56 relapsed multiple myeloma 56 Scandinavian Simvastatin Survival 56 KRAS mutations occur 56 Endovascular Valve Edge 56 retrospective cohort 56 IMC #B 56 non nucleoside inhibitor 56 mcg albinterferon alfa 2b 56 AEGR 56 Apoptone 56 NSABP 56 huN# DM1 56 Investigational Oral 56 relapsing multiple sclerosis 56 abacavir lamivudine 56 vinorelbine tartrate 56 Myelodysplastic Syndrome MDS 56 mg q#h 56 aldosterone antagonists 56 goserelin 56 multicentre 56 Begins Dosing 56 PI3K/Akt pathway inhibitor 56 r hGH 56 CBLC# 56 Tarceva TM 56 Peginterferon alfa 2b 56 Pertuzumab 56 nonmetastatic 56 headache nasopharyngitis 56 relapsed myeloma 56 BiTE antibody MT# 56 phase 2a 56 LEUKINE 56 Randomized Clinical Trials 56 Daclizumab 56 DDP# 56 fostamatinib 56 Major Depressive Disorder MDD 56 Multicenter Randomized Double 56 Raloxifene STAR 56 JAK inhibitor 56 Randomized Controlled Trials 56 Phase 2b Clinical Trial 56 Virulizin ® 56 ziprasidone Geodon 56 Swedish Mammography Cohort 56 Callisto initiated 56 GRNCM1 56 ritonavir boosted 56 RE MODEL 56 NCT# 56 RESOLUTE clinical 56 thetreatment 56 Ispinesib SB # 56 brand ciclesonide HFA 56 Current Controlled Trials 56 #-# Full Text 56 Albuferon TM 56 pharmacodynamic PK PD 56 efavirenz EFV 56 Risk Stratification 56 paclitaxel cisplatin 56 atherothrombotic events 56 IIa clinical 56 ChronVac C R 56 preclinical pharmacokinetic 56 Novo TTF 56 Metastatic Melanoma 56 Clinical Trial Evaluating 56 STEALTH C 56 Microalbuminuria 56 QLT Plug Delivery 56 darunavir ritonavir 56 glatiramer acetate 56 Pharmacokinetics PK 56 Vidaza ® 56 PEARL SC 56 doxorubicin docetaxel 56 EOquin TM phase 56 Long Term Efficacy 56 bicifadine 56 triple nucleoside 56 nucleotide analog 56 ACAPODENE 56 Syncria R 56 GW# [003] 56 VEGFR2 inhibitor 56 Prodarsan ® 56 patients undergoing percutaneous 56 ALSYMPCA 56 Alzheimer disease cognitive impairment 56 PRoFESS 56 hormone refractory metastatic prostate 56 Gynecologic Oncology Group 56 CYT# QbG# 56 Lenocta 56 CoreValve System 56 Immune Tolerance Network 56 Glycopyrrolate 56 NeuroSTAT ® 56 Preclinical Study 56 DU #b 56 Pegasys plus Copegus 56 oxypurinol 56 cyclophosphamide methotrexate 56 First Patient Dosed 56 safinamide 56 controlled multicenter Phase 56 dose escalation Phase 56 Platelet Inhibition 56 lomitapide 56 Oncotype DX colon cancer 56 Ovarian Cancer Screening 56 quetiapine fumarate 56 TYGACIL 56 opioid induced bowel dysfunction 56 randomized placebo controlled 56 fallopian tube cancers 56 anastrazole 56 Nesiritide 56 inhaled AAT 56 Diabetes ACCORD 56 intravenous CK # 56 Ozarelix 56 Phase III psoriasis 56 phase IIb III 56 ENDEAVOR clinical 56 SABCS 56 CINQUIL 56 echocardiographic parameters 56 bone marrow reticulin deposition 56 Linagliptin 56 Kidney Int 56 bapineuzumab AAB 56 Traficet EN 56 Infarct